OptiNose (OPTN) Set to Announce Earnings on Tuesday

OptiNose (NASDAQ:OPTN - Get Free Report) will announce its earnings results before the market opens on Tuesday, May 14th. Analysts expect the company to announce earnings of ($0.10) per share for the quarter. OptiNose has set its Q1 2024 guidance at EPS.Parties that wish to listen to the company's conference call can do so using this link.

OptiNose (NASDAQ:OPTN - Get Free Report) last released its quarterly earnings data on Thursday, March 7th. The company reported ($0.09) earnings per share for the quarter, beating the consensus estimate of ($0.10) by $0.01. The firm had revenue of $19.87 million during the quarter, compared to the consensus estimate of $19.90 million. During the same quarter in the previous year, the firm earned ($0.17) earnings per share. On average, analysts expect OptiNose to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

OptiNose Price Performance

NASDAQ OPTN traded up $0.10 during trading on Friday, reaching $1.22. 853,754 shares of the company's stock traded hands, compared to its average volume of 2,145,028. OptiNose has a 12-month low of $0.80 and a 12-month high of $2.10. The firm has a market cap of $137.91 million, a price-to-earnings ratio of -3.81 and a beta of -0.10. The company's 50 day simple moving average is $1.34 and its two-hundred day simple moving average is $1.31.

Wall Street Analysts Forecast Growth

Several equities analysts recently issued reports on the stock. HC Wainwright reissued a "buy" rating and set a $5.00 price objective on shares of OptiNose in a report on Monday, April 29th. Lake Street Capital boosted their price target on OptiNose from $3.00 to $4.00 and gave the stock a "buy" rating in a research report on Monday, March 18th.

Insider Buying and Selling

In related news, insider Michael F. Marino III sold 15,059 shares of the business's stock in a transaction that occurred on Monday, March 18th. The shares were sold at an average price of $1.88, for a total transaction of $28,310.92. Following the completion of the transaction, the insider now owns 602,268 shares in the company, valued at approximately $1,132,263.84. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. In other news, CEO Ramy A. Mahmoud sold 19,198 shares of the company's stock in a transaction on Monday, March 18th. The shares were sold at an average price of $1.88, for a total value of $36,092.24. Following the sale, the chief executive officer now directly owns 1,331,278 shares of the company's stock, valued at approximately $2,502,802.64. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Michael F. Marino III sold 15,059 shares of the company's stock in a transaction on Monday, March 18th. The shares were sold at an average price of $1.88, for a total transaction of $28,310.92. Following the completion of the sale, the insider now directly owns 602,268 shares in the company, valued at $1,132,263.84. The disclosure for this sale can be found here. Insiders sold a total of 36,602 shares of company stock worth $68,812 in the last 90 days. 2.20% of the stock is owned by corporate insiders.

OptiNose Company Profile

OptiNose, Inc, a specialty pharmaceutical company, focuses on the development and commercialization of products for patients treated by ear, nose, throat, and allergy specialists in the United States. The company offers XHANCE, a therapeutic product utilizing its proprietary exhalation delivery system (EDS) that delivers a topically acting corticosteroid for the treatment of chronic rhinosinusitis with nasal polyps, as well as is in Phase IIIb clinical trial for treatment of chronic sinusitis; and Onzetra Xsail, a powder EDS device.